Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 3/20 | 0.44 |
| ▸ | CHUK | O15111 | 1/20 | 0.36 |
| ▸ | USP14 | P54578 | 1/20 | 0.36 |
| ▸ | TDP2 | O95551 | 7/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.34 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.34 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.34 |
| ▸ | CDC7 | O00311 | 1/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14329624 | 0.83 | TOP2A (0.42) | — | |
| SCHEMBL15865944 | 0.80 | KIF11 (0.42) | CYP19A1CHUKTDP2 | |
| SCHEMBL14329649 | 0.80 | MAPK10 (0.42) | CYP19A1CYP11B2CYP11B1CYP17A1 | |
| SCHEMBL14330540 | 0.79 | MAOA (0.40) | — | |
| SCHEMBL14329632 | 0.78 | TOP2A (0.33) | — | |
| SCHEMBL14329646 | 0.78 | KCNH2 (0.34) | CYP19A1CDC7 | |
| SCHEMBL14329639 | 0.78 | TOP2A (0.40) | CYP11B1NCOA3 | |
| SCHEMBL14329611 | 0.76 | MAPK10 (0.39) | CYP19A1CDC7 | |
| SCHEMBL14330617 | 0.76 | REN (0.36) | — | |
| SCHEMBL14329614 | 0.75 | KIF11 (0.38) | CYP19A1CHUKTDP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8771844-B2 | Heterocyclic compound and organic light-emitting diode and flat display device including the heterocyclic compound | SAMSUNG DISPLAY CO., LTD. (KR) | 2014-07-08 | — | — | US | disclosed |
| US-20120326135-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DIODE AND FLAT DISPLAY DEVICE INCLUDING THE HETEROCYCLIC COMPOUND | SAMSUNG DISPLAY CO., LTD. (KR) | 2012-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120326135-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DIODE AND FLAT DISPLAY DEVICE INCLUDING THE HETEROCYCLIC COMPOUND | DDT, DRD1, HTR3D | CYP19A1 57/4885CHUK 980/4885USP14 3289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.